Intervention

Glucagon

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 43 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials43

Recruiting1

Common conditions25

Lead sponsors shown15

Clinical trials

43 shown

Effect of Glucagon on Fasting Insulin Secretion and Glucose Metabolism in Subjects Without Type 2 DiabetesNCT06424106 · 2025-04-01

Human Models of Selective Insulin Resistance: Pancreatic ClampNCT06558422 · 2027-01-01

NOT_YET_RECRUITING

Studies of Insulin and Glucagon Action in the LiverNCT07300982 · 2026-10-01

NOT_YET_RECRUITING

Research Study in Japan to Compare Dasiglucagon With Glucagon in Treating Very Low Levels of Blood Sugar in Asian Adults With Type 1 Diabetes and Testing of Dasiglucagon for the Same Condition in Japanese AdolescentsNCT06588504 · 2024-09-10

Dexamethasone/Pancreatic Clamp P&FNCT06126354 · 2024-07-01

Glucagon Enhanced Insulin Absorption in Diabetes Mellitus Type 1NCT05960565 · 2023-12-22

Pancreatic Clamp in NAFLDNCT05724134 · 2023-08-29

Dual-Hormone Closed-Loop Glucose Control in Adolescents With Type 1 DiabetesNCT04949867 · 2021-05-20

Copeptin After a Subcutaneous Stimulation With Glucagon in AdultsNCT04550520 · 2020-09-28

A Trial to Investigate Hyperglycemic and Hypoglycemic Excursions in Subjects With Type 1 DiabetesNCT04712266 · 2020-09-15

Metabolic Adaptation to High-frequent Hypoglycaemia in Type 1 DiabetesNCT05095259 · 2019-12-16

Glucagon Regulation of Glucose MetabolismNCT04347252 · 2019-09-24

Dual-hormone Closed-loop Glucose Control in Type 1 DiabetesNCT04053712 · 2019-07-16

Phenotypic and Genotypic Characterization of New-onset Type I DiabetesNCT04007809 · 2019-06-15

ACTIVE_NOT_RECRUITING

Liver Glycogen and Hypoglycemia in HumansNCT03241706 · 2018-08-02

ACTIVE_NOT_RECRUITING

Hepatic Metabolic Changes in Response to Glucagon InfusionNCT03526445 · 2018-05-01

Glucagon Infusion in T1D Patients With Recurrent Severe Hypoglycemia: Effects on Counter-Regulatory ResponsesNCT03490942 · 2018-03-15

First Research Study to Compare a Possible New Medicine NNC9204-1513 to the Medicine Glucagon, in Healthy People.NCT03444467 · 2018-02-05

Closed-loop Control of Postprandial Glucose Levels in Children and Adults With Type 1 DiabetesNCT02490098 · 2018-01-01

Effect of Prolonged (72 Hour) Glucagon Administration on Energy Expenditure in Healthy Obese SubjectsNCT03139305 · 2017-10-24

ACTIVE_NOT_RECRUITING

Efficacy of Glucagon In the Prevention of Hypoglycemia During Mild ExerciseNCT03217175 · 2017-08-18

Intranasal Glucagon and Energy BalanceNCT03650582 · 2017-06-06

Glucose Response of G-Pen (Glucagon Injection) in Pediatric T1D PatientsNCT03091673 · 2017-03-27

A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes MellitusNCT02910518 · 2017-02-17

Feasibility Trial Testing the Bionic Pancreas With ZP4207NCT02971228 · 2016-11-01

To Determine Tolerability to Glucagon Infusion in Obese SubjectsNCT02817659 · 2016-11-01

ACTIVE_NOT_RECRUITING

Safety of Overestimation of a Meal Insulin Bolus in the Context of Dual-hormone Closed-loop Operation - Part 2NCT02798250 · 2016-06-01

Effect of Ethanol Intoxication on the Anti-Hypoglycemic Action of GlucagonNCT02516150 · 2016-03-01

Safety of Overestimation of a Meal Insulin Bolus in the Context of Dual-hormone Closed-loop OperationNCT02626936 · 2016-01-01

Hyperglucagonaemia in Patients With Type 2 Diabetes - Role of Glucagon ClearanceNCT02475421 · 2015-05-01

Treatment of Low Blood Sugar With Glucagon Among Patients With Type 1 DiabetesNCT02232971 · 2014-09-01

Effects of Glucagon Administration on Energy ExpenditureNCT02237053 · 2014-09-01

Trial to Compare the Relative Pharmacodynamic Properties of Different Glucagon DosagesNCT01916265 · 2013-08-01

Efficacy of Small Subcutaneous Glucagon Dose to Treat Hypoglycemia in Adults With Type 1 DiabetesNCT01828125 · 2013-04-01

Study of LY2409021 in Participants With Type 1 DiabetesNCT01640834 · 2012-07-01

Physiologic Response to Glucagon at Varying Insulin LevelsNCT01483651 · 2011-11-01

Effect of LY2189265 on Insulin Secretion in Response to Intravenous GlucoseNCT01300260 · 2011-02-01

Safety Study of Repeated Doses of Glucagon on Animal Starch in the LiverNCT01986231 · 2011-01-01

To Evaluate the Response to Glucagon During HypoglycemiaNCT00817271 · 2009-02-01

A Phase 1 Study to Evaluate the Safety and Tolerability of GSK1362885 in Healthy Normal SubjectsNCT00823940 · 2009-01-13

Sensor-Augmented Insulin Delivery: Insulin Plus Glucagon Versus Insulin AloneNCT00797823 · 2008-11-01

A Study of MK-0893 on Glucagon-Induced Glycemic Excursion in Healthy Male Participants Following Intravenous Administration of Glucagon, Sandostatine® and Insulin (MK-0893-002)NCT02012166 · 2005-07-01

Closed-loop Control of Glucose Levels (Artificial Pancreas) for 15 Weeks in Adolescents and Adults With Type 1 DiabetesNCT02846857

Common conditions

Leading sponsors

Institut de Recherches Cliniques de Montreal 5 AdventHealth Translational Research Institute 3 Columbia University 3 Legacy Health System 3 Steno Diabetes Center Copenhagen 3 Eli Lilly and Company 2 Massachusetts General Hospital 2 Novo Nordisk A/S 2 Xeris Pharmaceuticals 2 Abvance Therapeutics 1 AstraZeneca 1 David D'Alessio, M.D. 1 Duke University 1 GlaxoSmithKline 1 Hvidovre University Hospital 1

Trial status mix

COMPLETED26

ACTIVE_NOT_RECRUITING4

WITHDRAWN4

TERMINATED3

UNKNOWN3

NOT_YET_RECRUITING2

RECRUITING1

Phase mix

PHASE118

PHASE211

NA9

PHASE44

PHASE32

EARLY_PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.